AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.57
−0.72%0
Insider buys (3m)
12
Insider sells (3m)
-$2.1M
Net value (3m)
-3.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 18, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 12,394 | $16 |
| Sep 18, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 12,394 | $9.88 |
| Sep 11, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 10,185 | $18 |
| Sep 11, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 10,185 | $8.04 |
| Sep 1, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 679 | $8.04 |
| Sep 1, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 679 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 2,876 | $9.88 |
| Aug 19, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,000 | $13 |
| Aug 19, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 1,000 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 3,749 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 31,031 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | Sale | 37,945 | $20 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 37,945 | $9.88 |
| Aug 19, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | M-Exempt | 31,031 | $9.88 |
| Aug 12, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 679 | $20 |
| Aug 12, 2026 | Riley Jennifer · officer: Chief Strategy Officer | Sale | 2,655 | $20 |
| Aug 12, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 679 | $8.04 |
| Jul 29, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 1,000 | $20 |
| Jul 29, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,000 | $13 |
| Jul 2, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 4,654 | $20 |
| Jul 2, 2026 | Lind Kevin Robert · director | A-Award | 1,105 | $18 |
| Jul 2, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 2,875 | $13 |
| Jul 2, 2026 | Jain Rita · director | A-Award | 1,080 | $18 |
| Jul 2, 2026 | Philip Ron M · director | A-Award | 69 | $18 |
| Jul 2, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,779 | $8.04 |
| Jun 25, 2026 | Doyle Mittie · officer: Chief Medical Officer | Sale | 1,450 | $18 |
| Jun 25, 2026 | Philip Ron M · director | A-Award | 40,200 | $18 |
| Jun 25, 2026 | Doyle Mittie · officer: Chief Medical Officer | M-Exempt | 1,450 | $8.04 |
| Jun 12, 2026 | VARKI PAUL · officer: Chief Legal Officer | F-InKind | 1,081 | $13 |
| Jun 12, 2026 | Sullivan Christopher Ryan · officer: Chief Financial Officer | F-InKind | 138 | $13 |
Institutional positioning
13F filings over the trailing two quarters
New 89Increased 79Reduced 40Sold out 27
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 5,100,216 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 4,365,553 | Aug 7, 2026 |
| Deep Track Capital, LP | New Position | 3,610,000 | Aug 14, 2026 |
| Caligan Partners LP | Increased | 3,163,866 | Aug 14, 2026 |
| TCG Crossover Management, LLC | Increased | 3,017,120 | Aug 14, 2026 |
| Affinity Asset Advisors, LLC | Increased | 2,900,000 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 2,889,287 | Aug 7, 2026 |
| FMR LLC | Increased | 2,879,481 | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 2,498,000 | Aug 14, 2026 |
| Point72 Asset Management, L.P. | Increased | 2,387,026 | Aug 14, 2026 |
| Avoro Capital Advisors LLC | Increased | 2,333,333 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,264,246 | Aug 13, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | New Position | 2,162,684 | May 15, 2026 |
| BVF INC/IL | Increased | 2,075,545 | Aug 14, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 1,913,829 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 18, 2026